journal article·2022-12Open access

Human Islet Amyloid Polypeptide (hIAPP) Protofibril‐Specific Antibodies for Detection and Treatment of Type 2 Diabetes

Angelina S. Bortoletto, W. Vallen Graham, Gabriella Trout, Alessandra Bonito‐Oliva, Manija A. Kazmi, Jing Gong, Emily Weyburne, Brandy L. Houser, Thomas P. Sakmar, Ronald J. Parchem

Advanced Science· Volume 9· Issue 34

Abstract

Abstract Type 2 diabetes mellitus (T2D) is a major public health concern and is characterized by sustained hyperglycemia due to insulin resistance and destruction of insulin‐producing β cells. One pathological hallmark of T2D is the toxic accumulation of human islet amyloid polypeptide (hIAPP) aggregates. Monomeric hIAPP is a hormone normally co‐secreted with insulin. However, increased levels of hIAPP in prediabetic and diabetic patients can lead to the formation of hIAPP protofibrils, which are toxic to β cells. Current therapies fail to address hIAPP aggregation and current screening modalities do not detect it. Using a stabilizing capping protein, monoclonal antibodies (mAbs) can be developed against a previously nonisolatable form of hIAPP protofibrils, which are protofibril specific and do not engage monomeric hIAPP. Shown here are two candidate mAbs that can detect hIAPP protofibrils in serum and hIAPP deposits in pancreatic islets in a mouse model of rapidly progressing T2D. Treatment of diabetic mice with the mAbs delays disease progression and dramatically increases overall survival. These results demonstrate the potential for using novel hIAPP protofibril‐specific mAbs as a diagnostic screening tool for early detection of T2D, as well as therapeutically to preserve β cell function and target one of the underlying pathological mechanisms of T2D.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Alzheimer's disease research and treatments · Amyloidosis: Diagnosis, Treatment, Outcomes · Endoplasmic Reticulum Stress and Disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center for Cell and Gene Therapy Stem Cells and Regenerative Medicine Center Department of Neuroscience Department of Molecular and Cellular Biology Translational Biology and Molecular Medicine Program Medical Scientist Training Program Baylor College of Medicine One Baylor Plaza Houston TX 77030 USA

Laboratory of Chemical Biology & Signal Transduction The Rockefeller University 1230 York Avenue New York NY 10065 USA

Celdara Medical 16 Cavendish Court Lebanon NH 03766 USA

Department of Neurobiology, Care Sciences, and Society Center for Alzheimer Research Division of Neurogeriatrics Karolinska Institutet Solna 17164 Sweden

Funding

National Institutes of Health · National Institute of Child Health and Human Development · National Heart, Lung, and Blood Institute · NHLBI Division of Intramural Research · Small Business Innovation Research

References (42)

Show source-provided references
1. International Diabetes Federation · 2021
2. 10.2337/dc14-103610.2337/dc14-1036 ↗
3. 10.1186/s40842-019-0080-010.1186/s40842-019-0080-0 ↗
4. 10.2337/diabetes.40.3.31010.2337/diabetes.40.3.310 ↗
5. 10.4239/wjd.v7.i9.18910.4239/wjd.v7.i9.189 ↗
6. 10.1124/mol.56.1.23510.1124/mol.56.1.235 ↗
7. 10.1016/j.neuroscience.2019.11.03610.1016/j.neuroscience.2019.11.036 ↗
8. 10.1021/ja710484d10.1021/ja710484d ↗
9. 10.1039/C4MT00130C10.1039/C4MT00130C ↗
10. 10.1016/j.bbamem.2018.02.02010.1016/j.bbamem.2018.02.020 ↗
11. 10.1073/pnas.192226711710.1073/pnas.1922267117 ↗
12. 10.3389/fmolb.2021.75742510.3389/fmolb.2021.757425 ↗
13. 10.1021/acs.chemrev.0c0112210.1021/acs.chemrev.0c01122 ↗
14. 10.1021/acs.chemrev.0c0098110.1021/acs.chemrev.0c00981 ↗
15. 10.1016/S0531-5565(03)00004-410.1016/S0531-5565(03)00004-4 ↗
16. 10.1021/ar200189b10.1021/ar200189b ↗
17. 10.1016/j.ijbiomac.2019.06.05010.1016/j.ijbiomac.2019.06.050 ↗
18. 10.1007/s00125-003-1304-410.1007/s00125-003-1304-4 ↗
19. 10.2337/db13-086310.2337/db13-0863 ↗
20. 10.1038/s41598-017-14311-110.1038/s41598-017-14311-1 ↗
21. 10.1172/JCI8521010.1172/JCI85210 ↗
22. 10.1016/j.jmb.2009.01.06110.1016/j.jmb.2009.01.061 ↗
23. 10.1016/j.nbd.2015.04.00910.1016/j.nbd.2015.04.009 ↗
24. 10.3109/13506129.2016.114802510.3109/13506129.2016.1148025 ↗
25. 10.1074/jbc.RA120.01550110.1074/jbc.RA120.015501 ↗
26. 10.1016/j.arr.2021.10133910.1016/j.arr.2021.101339 ↗
27. 10.1038/s41598-018-24501-010.1038/s41598-018-24501-0 ↗
28. 10.3390/vaccines911131610.3390/vaccines9111316 ↗
29. 10.1038/srep4288010.1038/srep42880 ↗
30. 10.1111/jcmm.1411910.1111/jcmm.14119 ↗
31. 10.1101/55880910.1101/558809 ↗
32. 10.1016/j.ymeth.2010.11.00910.1016/j.ymeth.2010.11.009 ↗
33. 10.1074/jbc.M112.39315710.1074/jbc.M112.393157 ↗
34. 10.1007/s12192-013-0448-510.1007/s12192-013-0448-5 ↗
35. 10.1038/ncomms1094810.1038/ncomms10948 ↗
36. 10.1038/nprot.2016.01010.1038/nprot.2016.010 ↗
37. 10.1016/j.bpc.2020.10651110.1016/j.bpc.2020.106511 ↗
38. 10.1016/j.bpc.2016.09.00710.1016/j.bpc.2016.09.007 ↗
39. 10.1073/pnas.93.14.728310.1073/pnas.93.14.7283 ↗
40. 10.1093/ilar.47.3.22510.1093/ilar.47.3.225 ↗
41. 10.2337/dc21-S00210.2337/dc21-S002 ↗
42. Greenfield E. A. · 2013